GALT vs KMX · $142.4M cap vs P/E 19, rev $25.88B
Galectin Therapeutics Inc (GALT) versus CarMax Inc (KMX) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
CarMax Inc (KMX) is a auto & truck dealerships company listed on US.
GALT does not have a complete income-statement cache yet.
Latest reported KMX revenue for 2026-02-28 was $25.88B. Net income was $247.3M. Revenue was down 1.8% from 2025-02-28 to 2026-02-28. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
GALT currently screens at market cap $142.4M. KMX currently screens at market cap $10.26B and trailing P/E 18.9.
Not investment advice. Open the GALT and KMX stock pages for the full models.
Not investment advice.